| Patient | Christopher Reeve |
|---|---|
| Date of birth | 1975-09-25 |
| Identifiers | MRN HR-ML024-SYN; SSN (made up) 000-24-7765 |
| Document date | 2026-10-26 |
| Author | Teresa Galloway, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review: respiratory care, skin, bladder and kidney surveillance, vaccines, and plans for the winter. [S]
Mr. Reeve returns six months after his first visit. He uses the pacer for three hours twice a day and the ventilator otherwise, with no respiratory infection since intake. His skin has stayed intact. He has had no symptoms of autonomic dysreflexia. His bladder and bowel programs are working, and he has had no unplanned hospital stay. His stool immunochemical test, HIV and hepatitis C screening from the preventive visit were negative. He feels well and wants to be protected for the winter, when he plans to keep traveling. [S]
| Element | Detail |
|---|---|
| Breathing | Pacer three hours twice a day; no infections |
| Skin | Intact |
| Screening results | Stool test, HIV and hepatitis C negative |
| Mood | Good; PHQ-9 2 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight change |
| Respiratory | Negative | Secretions thin and clear |
| Cardiovascular | Negative | No pounding headaches or flushing; no leg swelling |
| Genitourinary | Negative | Catheter draining well |
| Integumentary | Negative | No lasting redness |
| Psychiatric | Negative | Mood good |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sennosides 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 2026-04-13 | active | S |
| Nitroglycerin 2% ointment, one inch to the skin of the chest only if systolic blood pressure stays at 150 mmHg or higher after the first steps of the autonomic dysreflexia plan; wipe off when pressure falls | As needed for autonomic dysreflexia, under the written plan | Topical route | 2026-04-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets up to three times a day as needed for neck and shoulder aching | Two tablets up to three times a day as needed | Oral route | 2026-04-13 | active | S |
| Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-04-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-26 | Body height | 193 | cm | S |
| 2026-10-26 | Body weight | 83 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 60 | /min | S |
| 2026-10-26 | Respiratory rate | 12 | /min | S |
| 2026-10-26 | Body temperature | 36.3 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-26 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.49 | mg/dL | 0.74-1.35 mg/dL | Low | S |
| 2026-10-26 | Cystatin C [Mass/volume] in Serum or Plasma | 0.91 | mg/L | 0.53-0.95 mg/L | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Cystatin C-based formula/1.73 sq M | 92 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-26 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5.2 g/dL | Normal | S |
| 2026-10-26 | Braden scale total score | 12 | {score} | S | ||
| 2026-10-26 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 83.0 kg by chair scale; blood pressure 104/64, pulse 60 |
| Respiratory | On the ventilator during the visit; clear; stoma and pacer lead sites clean |
| Skin | Intact at all pressure points; Braden score 12 |
| Extremities | No leg swelling; modified Ashworth 1 in the legs |
| Psychiatric | Engaged and good-humored |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic incomplete C2 tetraplegia (ASIA grade C) from a traumatic spinal cord injury in a riding fall eight years ago, with partial late recovery of sensation and movement; uses a power wheelchair and has 24-hour nursing support; at risk of autonomic dysreflexia; synthetic modern episode linked to his documented injury and his physicians' published report | active | confirmed | G82.52 | S — Synthetic modern coding of the documented injury and the published ASIA grade. |
| Chronic ventilatory failure from the high cervical injury: dependent on a ventilator through a tracheostomy, with a diaphragm pacing system implanted some weeks ago and a conditioning program to lengthen time on the pacer; synthetic modern episode linked to his documented ventilator use and pacing | active | confirmed | Z99.11 | S — Synthetic modern coding of the documented ventilator dependence. |
| Neurogenic bladder after spinal cord injury, managed with an indwelling catheter | active | confirmed | N31.9 | S — Synthetic; expected with this level of injury. No public source describes his bladder care. |
| Neurogenic bowel after spinal cord injury, managed with a daily morning bowel program | active | confirmed | K59.2 | S — Synthetic; expected with this level of injury. No public source describes his bowel care. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Autonomic dysreflexia: episodes, baseline blood pressure, written plan, and nurse training | Every visit | Completed today | No episodes in six months; plan reviewed with two new relief nurses |
| Survey | Skin check and Braden scale | Every visit | Completed today | Intact; Braden 12 |
| Self-management | Seating, cushion, and pressure mapping | At least yearly and after any change in equipment, weight or skin | Up to date | Mapped and adjusted two months ago |
| Self-management | Catheter care and urinary symptoms | Every visit | Completed today | No symptoms; changes on schedule |
| Laboratory | Kidney function (cystatin C; creatinine unreliable with low muscle mass) | At baseline, then every 6 to 12 months | Completed today | Cystatin C 0.91 mg/L, eGFR 92; sodium 138, potassium 4.1 mmol/L; creatinine 0.49 mg/dL |
| Imaging | Kidney and bladder ultrasound | Yearly | Up to date | Normal upper tracts six months ago; next in six months |
| Laboratory | Blood count and albumin | Every 6 to 12 months | Completed today | White cells 6.8, hemoglobin 13.4 g/dL; albumin 4.0 g/dL |
| Self-management | Bowel program | Every visit | Completed today | Effective |
| Examination | Pacer conditioning, oxygen saturation, and secretion clearance | Every visit | Completed today | Pacer three hours twice a day; no infections; winter plan written |
| Self-management | Backup ventilator, suction, cough-assist device, and power plan | Every visit, with monthly checks by his nurses | Completed today | Checks up to date; winter power plan confirmed |
| Imaging | Bone density (DXA of the hip and knee regions) | Baseline, then every 2 years | Up to date | Next in about eighteen months |
| Laboratory | Lipids, A1c, and blood pressure | Yearly | Due | Due at the one-year review |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 to 12 months and with any change | Completed today | PHQ-9 2 |
| Survey | Pain score and pain plan | Every visit | Completed today | Pain score 2 |
| Examination | Spasticity and range of motion | Every visit | Completed today | Modified Ashworth 1; daily ranging |
| Examination | Venous thromboembolism: leg swelling | Every visit; prophylaxis only during acute illness, surgery or immobilization | Completed today | No leg swelling |
| Self-management | Influenza, COVID-19 and hepatitis B vaccines | Influenza and COVID-19 each season; hepatitis B two doses a month apart | Completed today | All given today; hepatitis B dose 2 in one month |
| Referral | Spinal cord injury medicine review | At least yearly | Up to date | Next review with Dr. Kovac after the winter |
Goal progress:
Immunizations given today: Influenza vaccine, inactivated, this season; COVID-19 vaccine, mRNA, this season; Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]
Guideline basis: Evaluation and Management of Autonomic Dysreflexia and Other Autonomic Dysfunctions: Preventing the Highs and Lows (Consortium for Spinal Cord Medicine) (2021); Pressure Ulcer Prevention and Treatment Following Spinal Cord Injury: A Clinical Practice Guideline for Health-Care Providers, Second Edition (Consortium for Spinal Cord Medicine) (2014); Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers (Consortium for Spinal Cord Medicine) (2006); The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up (2021); Management of Neurogenic Bowel Dysfunction in Adults after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers (Consortium for Spinal Cord Medicine) (2021); Respiratory management following spinal cord injury: a clinical practice guideline for health-care professionals (Consortium for Spinal Cord Medicine) (2005); Bone Health and Osteoporosis Management in Individuals with Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers (Consortium for Spinal Cord Medicine) (2022); Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers (Consortium for Spinal Cord Medicine) (2018); Management of Mental Health Disorders, Substance Use Disorders, and Suicide in Adults with Spinal Cord Injury: Clinical Practice Guideline for Healthcare Providers (Consortium for Spinal Cord Medicine) (2021); Prevention of Venous Thromboembolism in Individuals with Spinal Cord Injury: Clinical Practice Guidelines for Health Care Providers, 3rd ed. (Consortium for Spinal Cord Medicine) (2016); Evaluation and Management of Pain After Spinal Cord Injury (Consortium for Spinal Cord Medicine) (2026); CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Hepatitis B dose 2 in one month and the second zoster dose by early in the new year. Review in three months, or the same day for fever, a chest infection, skin redness that does not fade, or autonomic dysreflexia that does not settle with the plan. [S]